Encoded Therapeutics is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. The company's mission is to unlock new opportunities for viral gene therapy and gene editing, and to develop new technologies to overcome the current limitations of gene therapy. Encoded's lead program is focused on Dravet syndrome, a rare and severe form of epilepsy that begins in infancy. The company is also developing gene therapies for other neurological and metabolic disorders, including Tay-Sachs disease, Gaucher disease, and Wilson disease. Encoded was founded in 2014 and is headquartered in South San Francisco, California.